… For advanced NSCLC harboring activating EGFR mutations, first-line treatment with an
EGFRTKI is recommended as a standard treatment of care, and now a third-generation …

… 85% of all lung cancers, and most cases … EGFR tyrosine kinase inhibitors (EGFR-TKIs) have
been approved by the FDA for the treatment of advanced NSCLC since 2003 (5). EGFR-TKIs …

… tyrosine kinase inhibitors (EGFR-TKIs)-rechallenged therapy for EGFR-mutant non-small
cell lung cancer (… Considering the high interrelation between EGFR and vascular endothelial …

… and acquired resistance to EGFR TKIs in lung cancer and colorectal cancer through activating
the … cognition about mechanisms of acquired resistance to EGFR-TKIs in lung cancer [85]. …

… EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors
… Most of the human lung cancer cell lines examined in this study were established by the …

… Both epidermal growth factor receptor (EGFR) mutation and anaplastic lymphoma … lung
cancer (NSCLC) that can significantly benefit from EGFR TKI (gefitinib and erlotinib) and ALK TKI …

… molecules [12], by which EGFR tyrosine kinase inhibitors (EGFR-TKIs) exert their dramatic
effects in patients with EGFR mutated lung cancer. EGFR mutations have been identified in …

… of EGFR-TKIs and prolong survival in patients with lung cancer receiving EGFR-TKI therapy.
… to determine the effect of statin use in patients with lung cancer receiving EGFR-TKI therapy. …

… to gefitinib in a gefitinib-sensitive lung cancer cell line. Moreover, cMET … tumor samples
of EGFR-TKI-treated NSCLC patients for potential biological markers of intrinsic EGFR-TKI …

… The most common mechanism of resistance to first-generation TKIs is marked by T790 M, …
2nd generation EGFR TKIs [Citation11]. Osimertinib is an irreversible third-generation TKI that …